Association of C34T AMPD1 gene polymorphism with features of metabolic syndrome in patients with coronary artery disease or heart failure

References

• Morisaki T., Sabina R. L., Holmes E. W. Adenylate deaminase. A multigene family in humans and rats. J Biol Chem 1990; 265: 11482–6
   PubMed Web of Science ®Google Scholar
• Morisaki T., Gross M., Morisaki H., Pongratz D., Zöllner N., Holmes E. W. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci USA 1992; 89: 6457–61
   PubMed Web of Science ®Google Scholar
• Norman B., Mahnke‐Zizelman D. K., Vallis A., Sabina R. L. Genetic and other determinants of AMP deaminase activity in healthy adult skeletal muscle. J Appl Physiol 1998; 85: 1273–8
   PubMed Web of Science ®Google Scholar
• Sabina R. L., Swain J. L., Patten B. M., Ashizawa T., O'Brien W. E., Holmes E. W. Disruption of the purine nucleotide cycle. A potential explanation for muscle dysfunction in myoadenylate deaminase deficiency. J Clin Invest 1980; 66: 1419–23
   PubMedGoogle Scholar
• Gross M. Clinical heterogeneity and molecular mechanisms in inborn muscle AMP deaminase deficiency. Inherit Metab Dis 1997; 20: 186–92
   PubMed Web of Science ®Google Scholar
• Tarnopolsky M. A., Parise G., Gibala M. J., Graham T. E., Rush J. W. Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans. J Physiol 2001; 533: 881–9
   PubMed Web of Science ®Google Scholar
• Kalsi K. K., Yuen A. H., Rybakowska I. M., Johnson P. H., Slominska E., Birks E. J., Kaletha K., Yakoub M. H., Smolensk R. T. Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation – a potential mechanism of protection in heart failure. Cardiovasc Res 2003; 59: 678–84
   PubMed Web of Science ®Google Scholar
• Loh E., Rebbeck T. R., Mahoney P. D., DeNofrio D., Swain J. L., Holmes E. W. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 1999; 99: 1422–5
   PubMed Web of Science ®Google Scholar
• Gastmann A., Sigusch H. H., Henke A., Reinhardt D., Surber R., Gastmann O., Figulla H. R. Role of adenosine monophosphate deaminase‐1 gene polymorphism in patients with congestive heart failure (influence on tumor necrosis factor‐alpha level and outcome). Am J Cardiol 2004; 93: 1260–4
   PubMedGoogle Scholar
• Yazaki Y., Muhlestein J. B., Carlquist J. F., Bair T. L., Horne B. D., Renlund D. G., Andersson J. L. A common variant of the AMPD1 gene predicts improved survival in patients with ischemic left ventricular dysfunction. J Card Fail 2004; 10: 316–20
   PubMedGoogle Scholar
• Anderson J. L., Habashi J., Carlquist J. F., Muhlestein J. B., Horne B. D., Bair T. L., Pearson R. R., Hart N. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol 2000; 36: 1248–52
   PubMed Web of Science ®Google Scholar
• Andreassi M. G., Botto N., Laghi‐Pasini F., Manfredi S., Ghelarducci B., Farneti A., Solinas M., Biagin A., Picano E. AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization. Int J Cardiol 2005; 101: 191–5
   PubMedGoogle Scholar
• Kolek M. J., Carlquist J. F., Thaneemit‐Chen S., Lazzeroni L. C., Whiting B. M., Horne B. D., Muhlestein J. B., Lavor P., Andersson J. L. The role of a common adenosine monophosphate deaminase (AMPD)‐1 polymorphism in outcomes of ischemic and nonischemic heart failure. J Card Fail 2005; 11: 677–83
   PubMedGoogle Scholar
• de Groote P., Lamblin N., Helbecque N., Mouquet F., Hermant X., Amouyel P., Dallongeville J., Bauters C. The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: a study in 686 consecutive patients. Am Heart J 2006; 152: 736–41
   PubMed Web of Science ®Google Scholar
• Collins R. P., Palmer B. R., Pilbrow A. P., Frampton C. M., Troughton R. W., Yandle T. G., Skelton L., Richards A. M., Cameron V. A. Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post‐myocardial infarction patients. Am Heart J 2006; 152: 312–20
   PubMedGoogle Scholar
• Goodarzi M. O., Taylor K. D., Guo X., Quinones M. J., Cui J., Li X., Hang T., Yang H., Holmes E., Hsueh WA., Olefsky J., Rotter JL. Variation in the gene for muscle‐specific AMP deaminase is associated with insulin clearance, a highly heritable trait. Diabetes 2005; 54: 1222–7
   PubMedGoogle Scholar
• Guo S. W., Thompson E. A. Performing the exact test of Hardy‐Weinberg proportion for multiple alleles. Biometrics 1992; 48: 361–72
   PubMed Web of Science ®Google Scholar
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 2005. Available at: http://www.idf.org
   Google Scholar
• Agewall S., Norman B. Association between AMPD1 gene polymorphism and coagulation factors in patients with coronary heart disease. Pathophysiol Haemost Thromb 2006; 35: 440–4
   PubMedGoogle Scholar
• Rico‐Sanz J., Rankinen T., Joanisse D. R., Leon A. S., Skinner J. S., Wilmore J. H., Rao D. C., Bouchard C. HERITAGE Family study. Associations between cardiorespiratory responses to exercise and the C34T AMPD1 gene polymorphism in the HERITAGE Family Study. Physiol Genomics 2003; 14: 161–6
   PubMed Web of Science ®Google Scholar
• Fischer H., Esbjörnsson M., Sabina R. L., Strömberg A., Peyrard‐Janvid M., Norman B. AMP deaminase deficiency is associated with lower sprint cycling performance in healthy subjects. J Appl Physiol 2007; 103: 315–22
   PubMed Web of Science ®Google Scholar
• Hand B. D., Roth S. M., Roltsch M. H., Park J. J., Kostek M. C., Ferrell R. E., Brown M. D. AMPD1 gene polymorphism and the vasodilatory response to ischemia. Life Sci 2006; 79: 1413–18
   PubMedGoogle Scholar
• Winder W. W., Hardie D. G. AMP‐activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999; 277: E1–10
   PubMed Web of Science ®Google Scholar
• Steinberg G. R., Jorgensen S. B. The AMP‐activated protein kinase: role in regulation of skeletal muscle metabolism and insulin sensitivity. Mini Rev Med Chem 2007; 7: 519–26
   PubMed Web of Science ®Google Scholar
• Towler M. C., Hardie D. G. AMP‐activated protein kinase in metabolic control and insulin signaling. Circ Res 2007; 100: 328–41
   PubMed Web of Science ®Google Scholar
• Gerbitz K. D., Gempel K., Brdiczka D. Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit. Diabetes 1996; 45: 113–26
   PubMed Web of Science ®Google Scholar
• Bottini E., Gloria‐Bottini F. Adenosine deaminase and body mass index in non‐insulin‐dependent diabetes mellitus. Metabolism 1999; 48: 949–51
   PubMed Web of Science ®Google Scholar
• Gloria‐Bottini F., Bottini E., Lucarini N., Palmarino R. Further observations on the relationship between adenosine deaminase and body mass. Metab Clin Exp 1999; 48: 1336
   PubMedGoogle Scholar
• Thong F. S., Graham T. E. The putative roles of adenosine in insulin‐ and exercise‐mediated regulation of glucose transport and glycogen metabolism in skeletal muscle. Can J Appl Physiol 2002; 27: 152–78
   PubMedGoogle Scholar
• Palaniappan L., Carnethon M. R., Wang Y., Hanley A. J., Fortmann S. P., Haffner S. M., Wagenknecht L. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27: 788–93
   PubMed Web of Science ®Google Scholar